The Prospective comparison of ARNI with angiotensin-converting enzyme inhibitor to
Determine Impact on Global Mortality and morbidity in Heart Failure trial identified a marked …

Heart failure (HF) is associated to endothelial dysfunction that promotes the increase of
arterial stiffness thus augmenting myocardial damage. Sacubitril/Valsartan is used in the …

OBJECTIVE: The aim of the present study was to observe the effect of sacubitril valsartan on
cardiac function and vascular endothelial function in patients with chronic heart failure with …

The clinical syndrome of heart failure (HF) can be described as the reduced capacity of the
heart to deliver blood throughout the body. To compensate for inadequate tissue perfusion …

Background Sacubitril/valsartan, the first agent to be approved in a new class of drugs called
angiotensin receptor neprilysin inhibitors (ARNIs), has been shown to reduce cardiovascular …

Objectives: This study sought to describe the short-term health status benefits of angiotensin-
neprilysin inhibitor (ARNI) therapy in patients with heart failure and reduced ejection fraction …

Background—The angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696)
reduced cardiovascular morbidity and mortality compared with enalapril in patients with …

Background: Treatment with sacubitril-valsartan reduces mortality and heart failure (HF)
events in HF with reduced ejection fraction and may reduce HF hospitalization in women …

The angiotensin receptor/neprilysin inhibitor Sacubitril/Valsartan (Sac/Val) has been shown
to be beneficial in patients suffering from heart failure with reduced ejection fraction (HFrEF) …

Abstract The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker
Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on …